ArticleMolecular endocrinology (Baltimore, Md.)2008
Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.
Article in Molecular endocrinology (Baltimore, Md.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- High Expression Level of TRIP6 is Correlated with Poor Prognosis in Colorectal Cancer and Promotes Tumor Cell Proliferation and Migration.Biochemical genetics · 2025Article
- The LIM domain protein nTRIP6 modulates the dynamics of myogenic differentiation.Scientific reports · 2021Article
- Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57Frontiers in cell and developmental biology · 2021Article
- TRIP6 enhances stemness property of breast cancer cells through activation of Wnt/β-catenin.Cancer cell international · 2020Article
- Article
- Glucocorticoid and cytokine crosstalk: Feedback, feedforward, and co-regulatory interactions determine repression or resistance.The Journal of biological chemistry · 2017Review
- Understanding how long-acting βBritish journal of pharmacology · 2016Review
- Mineralocorticoid Receptor (MR) trans-Activation of Inflammatory AP-1 Signaling: DEPENDENCE ON DNA SEQUENCE, MR CONFORMATION, AND AP-1 FAMILY MEMBER EXPRESSION.The Journal of biological chemistry · 2016Article
- Review
- The LIM domain protein nTRIP6 acts as a co-repressor for the transcription factor MEF2C in myoblasts.Scientific reports · 2016Article
- Dual-Specificity Phosphatase 1 and Tristetraprolin Cooperate To Regulate Macrophage Responses to Lipopolysaccharide.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- The LIM domain protein nTRIP6 recruits the mediator complex to AP-1-regulated promoters.PloS one · 2014Article
- Nuclear receptors in inflammation control: repression by GR and beyond.Molecular and cellular endocrinology · 2013Review
- Signal-dependent fra-2 regulation in skeletal muscle reserve and satellite cells.Cell death & disease · 2013Article
- Article
- Anti-inflammatory effects of selective glucocorticoid receptor modulators are partially dependent on up-regulation of dual specificity phosphatase 1.British journal of pharmacology · 2012Article
- RsfA (YbeB) proteins are conserved ribosomal silencing factors.PLoS genetics · 2012Article
- Efficient recombinant production in mammalian cells using a novel IR/MAR gene amplification method.PloS one · 2012Article
- TRIP6: an adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity.Cellular signalling · 2011Review
- Negative regulation by nuclear receptors: a plethora of mechanisms.Trends in endocrinology and metabolism: TEM · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term activator protein (AP)-1 describes homodimeric and heterodimeric transcription factors composed of members of the Jun, Fos, and cAMP response element-binding protein (CREB)/activating transcription factor (ATF) families of proteins. Distinct AP-1 dimers, for instance the prototypical c-Jun:c-Fos and c-Jun:ATF2 dimers, are differentially regulated by signaling pathways and bind related yet distinct response elements in the regulatory regions of AP-1 target genes. Little is known about the dimer-specific regulation of AP-1 activity at the promoter of its target genes. We have previously shown that nTrip6, the nuclear isoform of the LIM domain protein Trip6, acts as an AP-1 coactivator. Moreover, nTrip6 is an essential component of glucocorticoid receptor (GR)-mediated trans-repression of AP-1, in that it mediates the tethering of GR to the promoter-bound AP-1. We have now discovered a striking specificity of nTrip6 actions determined by the binding preference of its LIM domains. We show that nTrip6 interacts only with Fos family members. Consequently, nTrip6 is a selective coactivator for AP-1 dimers containing Fos. nTrip6 also assembles activated GR to c-Jun:c-Fos-driven promoters. Neither nTrip6 nor GR are recruited to a promoter occupied by c-Jun:ATF2. Thus, only Fos-containing dimers are trans-repressed by GR. Thus, the dimer composition of AP-1 determines the mechanism of both the positive and negative regulation of AP-1 transcriptional activity. Interestingly, on a second level of action, GR represses the increase in transcriptional activity of c-Jun:ATF2 induced by c-Jun N-terminal kinase (JNK)-dependent phosphorylation. This repression depends on GR-mediated induction of MAPK phosphatase 1 (MKP-1) expression, which results in c-Jun N-terminal kinase inactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.